As of March 31, 2025, Immunovant’s (IMVT) cash and cash equivalents totaled approximately $714 million, providing runway for announced indications through GD readout expected in 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- IMVT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Gran Tierra, Immunovant, AIM, Cracker Barrel, JB Hunt: Insider Moves Unveiled!
- Immunovant’s Strategic Leadership and Portfolio Expansion Justify Buy Rating
- Immunovant downgraded to Neutral from Buy at UBS
- Immunovant’s Strategic Developments and Growth Potential Drive Buy Rating